Gracell Biotechnologies (shanghai) Co., Ltd.

This study tests a new treatment called GC012F for people with multiple myeloma that has come back or stopped responding to other therapies. GC012F uses a patient's own immune cells, which are modified in a lab to better find and attack cancer cells. The goal is to control the di…

This early-phase trial tests a new treatment called GC012F for people with AL amyloidosis that has come back or not responded to prior therapy. The therapy uses specially engineered immune cells to target two proteins on harmful cells. The study will enroll 9 adults to check safe…

This study is testing an experimental injection called GC012F in people with systemic lupus erythematosus (SLE) that hasn't responded well to standard treatments. Researchers will enroll 118 participants to check if the treatment is safe and if it helps reduce lupus symptoms over…